Continuous versus cyclic mesalazine therapy for patients affected by recurrent symptomatic uncomplicated diverticular disease of the colon

Digestive Diseases and Sciences

Volumn 52, Issue 3, 2007, Pages 671-674

  Tursi, Antonio ^a   Brandimarte, Giovanni ^b   Giorgetti, Gian Marco ^c   Elisei, Walter ^b  

^a Lorenzo Bonomo Hospital   (Italy)

^b Cristo Re Hospital   (Italy)

^c S EUGENIO HOSPITAL   (Italy)

Author keywords

Mesalazine; Recurrent symptomatic diverticular disease; Treatment

Indexed keywords

ESOMEPRAZOLE; MESALAZINE; RIFAXIMIN;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; COLON DIVERTICULOSIS; CONFIDENCE INTERVAL; CONTINUOUS INFUSION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSAGE SCHEDULE COMPARISON; DRUG EFFICACY; EPIGASTRIC PAIN; FEMALE; FOLLOW UP; HOSPITAL ADMISSION; HUMAN; INTERMETHOD COMPARISON; MALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RECURRENT DISEASE; SCORING SYSTEM; STROKE;

AGED; AGED, 80 AND OVER; DIVERTICULUM, COLON; FEMALE; HUMANS; MALE; MESALAMINE; MIDDLE AGED; PROSPECTIVE STUDIES; RECURRENCE; REMISSION INDUCTION; TREATMENT OUTCOME;

EID: 33847192839     PISSN: 01632116     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10620-006-9551-0     Document Type: Article

References (13)

1. West AB, Losada M (2004) The pathology of diverticulosis coli. J Clin Gastroenterol 38(Suppl 1):S11-S16
2. Tursi A (2004) Acute diverticulitis of the colon - current medical therapeutic management. Expert Opin Pharmacother 5:145-149
3. Tursi A, Brandimarte G, Daffinà R (2002) Long-term treatment with mesalazine and rifaximin versus rifaximin alone for the patients with recurrent attacks of acute diverticulitis of the colon. Dig Liver Dis 34:510-515
4. Brandimarte G, Tursi A (2004) Rifaximin plus mesalazine followed by mesalazine alone is highly effective in obtaining remission of symptomatic uncomplicated diverticular disease. Med Sci Monit 10:170-173
5. Tursi A, Brandimarte G, Giorgetti GM, Elisei W (2006) Mesalazine and/or Lactobacillus casei in preventing recurrence of symptomatic uncomplicated diverticular disease of the colon: a prospective, randomised, open-label study. J Clin Gastroenterol 40:312-316
6. DiMario F, Aragona G, Leandro G, Comparato G, Fanigliulo G, Cavallaro G, Cavestro GM, Iori V, Maino M, Moussa AM, Gnocchi A, Mazzocchi G, Franzé A (2005) Efficacy of Mesalazine in the Treatment of Symptomatic Diverticular Disease. Dig Dis Sci 50:581-586
7. Results of a Consensus Development Conference (1999) Diagnosis and treatment of diverticular disease. Surg Endosc 13:430-436
8. Latella G, Pimpo MT, Sottili S, Zippi M, Viscido A, Chiaramonte M, Frieri G (2003) Rifaximin improves symptoms of acquired uncomplicated diverticular disease of the colon. Int J Colorectal Dis 18:55-62
9. Grisham MB (2004) Oxidants and free radicals in inflammatory bowel disease. Lancet 344:859-861
10. Wood AJJ (1996) Inflammatory bowel disease. N Engl J Med 334:841-848
11. Gonçalves E, Almeida LM, Dinis TC (1998) Antioxidant activity of 5-aminosalicylic acid against peroxidation of phosphatidylcholine liposomes in the presence of alpha-tocopherol: a synergistic interaction? Free Rad Res 29:53-66
12. Comparato G, Fanigliulo L, Cavallaro LG, Aragona G, Cavestro GM, Liatopoulou S, Carloni C, Nervi G, Muzzetto P, Iori V, Maino M, Franzè A, Di Mario F (2006) Quality of life in uncomplicated diverticular disease: Is it another good reason for the treatment? Dig Liver Dis 38(Suppl 1):S178
13. Floch MH, Bina I (2004) The natural history of diverticulitis: fact and theory. J Clin Gastroenterol 38(Suppl 5):S2-7